Biosynex has announced sales of €196.6 million for 2022, down 49% on the previous year (-50% in organic terms, excluding the effect of acquisitions during the year).

The Group reports that, from the second quarter onwards, it had to contend with a sharp drop in sales of Covid-19 products in Europe.

The decline thus represents more than ME 200 over the full year, with Covid-19 products posting revenues of ME 140.9 in 2022, compared with ME 342.2 in 2021.

For 2023, the Group anticipates a further decline in activity around Covid-19 products. However, 'this activity remains resilient due to the endemic situation and the interest in the combined detection of viral respiratory infections (SARS-CoV-2, influenza, respiratory syncytial virus)', says Biosynex.


Copyright (c) 2023 CercleFinance.com. All rights reserved.